RESEARCH-USE BIOSIMILAR ANTIBODY
Frovocimab
Monoclonal antibody · IgG4
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9.
TARGETPCSK9
YMonoclonal antibody
CATALOGSC-BS-532
CATALOG NUMBERSC-BS-532
MOLECULAR WEIGHTApprox. 146.38 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9.
Frovocimab is a recombinant research-use antibody directed against PCSK9.